STOCK TITAN

Schedule 13G/A: American Century, Stowers Report 8.2% of Visteon

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Visteon Corporation received a Schedule 13G/A (Amendment No. 2) disclosing that American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research beneficially own 2,222,551 shares of common stock, representing 8.2% of the class. The cover pages report sole voting power of 2,173,962 shares and sole dispositive power of 2,222,551 shares. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The position is reported as of 06/30/2025, the filing is signed 08/14/2025, and an exhibit records consent to the joint filing.

Positive

  • Material ownership disclosure: Reporting parties beneficially own 2,222,551 shares (8.2%) of Visteon common stock.
  • Clear voting and dispositive figures: Sole voting power reported at 2,173,962 and sole dispositive power at 2,222,551 shares.
  • Passive intent certified: Filers state holdings were acquired and are held in the ordinary course of business and not to influence control.
  • Compliance and joint consent: Filing is an Amendment No. 2 Schedule 13G/A and includes an exhibit consenting to joint filing, demonstrating procedural compliance.

Negative

  • None.

Insights

TL;DR A material passive stake of 8.2% is disclosed; the filing signals institutional accumulation without stated intent to seek control.

The Schedule 13G/A shows a significant institutional position: 2,222,551 shares (8.2%) with reported sole voting power of 2,173,962 shares. Because the filers certified the holdings were acquired in the ordinary course and not to influence control, this is a passive-disclosure event rather than an activist advance. For investors, the filing provides clarity on major ownership concentration and who holds dispositive authority over the shares, but it does not indicate a change to governance or strategy.

TL;DR The disclosure of an >5% stake is material for ownership transparency but shows no stated intent to pursue control or nomination activities.

The document identifies the reporting persons and quantifies both voting and dispositive power, which is essential for governance mapping: sole voting power 2,173,962; sole dispositive power 2,222,551. The filers explicitly certify the securities are held in the ordinary course and not to change control, consistent with a Schedule 13G filing posture. The attached exhibit consenting to joint filing clarifies the reporting structure among the parties. This filing is material for shareholder registers and proxy mapping but does not itself signal activist governance action.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



American Century Investment Management, Inc.
Signature:American Century Investment Management, Inc.
Name/Title:/s/ John Pak / Senior Vice President
Date:08/14/2025
American Century Companies, Inc.
Signature:American Century Companies, Inc.
Name/Title:/s/ John Pak / Senior Vice President
Date:08/14/2025
Stowers Institute for Medical Research
Signature:Stowers Institute for Medical Research
Name/Title:/s/ Joselyn Verschelden / Authorized Signer
Date:08/14/2025
Exhibit Information

EXHIBIT Each of the undersigned hereby agrees and consents to the execution and joint filing on its behalf by American Century Investment Management, Inc. of this Schedule 13G respecting the beneficial ownership of the securities which are the subject of this schedule. Dated this 14th day of August, 2025. AMERICAN CENTURY INVESTMENT MANAGEMENT, INC. ("ACIM") AMERICAN CENTURY COMPANIES, INC. ("ACC") By: __/s/ John Pak___________ John Pak Senior Vice President, ACIM and ACC STOWERS INSTITUTE FOR MEDICAL RESEARCH, solely in its capacity as control entity of ACC By: __/s/ Joselyn Verschelden_________ Joselyn Verschelden Authorized Signer

FAQ

Who filed the Schedule 13G/A for Visteon (VC)?

The filing was made by American Century Investment Management, Inc.; American Century Companies, Inc.; and Stowers Institute for Medical Research.

How many Visteon shares are reported and what percent of the class do they represent?

The reporting parties beneficially own 2,222,551 shares, representing 8.2% of the class.

What voting and dispositive powers are reported?

The cover pages report sole voting power of 2,173,962 shares and sole dispositive power of 2,222,551 shares.

As of what date is the position reported?

The position is reported as of 06/30/2025.

Does the filing state an intent to influence control of Visteon?

No. The filers certify the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of changing or influencing control.

When was the Schedule 13G/A signed?

The signatures on the filing are dated 08/14/2025.
Visteon Corp

NASDAQ:VC

VC Rankings

VC Latest News

VC Latest SEC Filings

VC Stock Data

2.65B
26.99M
1.05%
111.91%
5.93%
Auto Parts
Motor Vehicle Parts & Accessories
Link
United States
VAN BUREN TOWNSHIP